From PsychonautWiki
(Redirected from Ethlad)
Jump to: navigation, search
Summary sheet: ETH-LAD
Molecular structure of ETH-LAD
Chemical Nomenclature
Common names ETH-LAD
Substitutive name 6-Ethyl-6-nor-lysergic acid diethylamide
Systematic name (6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide
Class Membership
Psychoactive class Psychedelic
Chemical class Lysergamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 15 - 30 µg
Light 30 - 60 µg
Common 60 - 150 µg
Strong 150 - 225 µg
Heavy 225 µg +
Total 8 - 12 hours
Onset 20 - 40 minutes
Come up 45 - 90 minutes
Peak 4 - 6 hours
Offset 2 - 4 hours
After effects 8 - 48 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

6-Ethyl-6-nor-lysergic acid diethylamide (also known as N-Ethyl-nor-lysergic acid N,N-diethylamide,[1] N-Ethyl-nor-LSD,[1] and ETH-LAD[1]) is a novel synthetic psychedelic of the lysergamide chemical class that is reported to produce an array of LSD-like psychedelic effects when administered. It is a close structural homolog of LSD and was first documented by Alexander Shulgin in his book TiHKAL ("Tryptamines I Have Known and Loved"), in which he notes the "modified visual distortion" it produces relative to LSD.[2]

This compound has been shown to be moderately to significantly more potent than LSD itself in animal models[3] with an active dose reported at between 40 and 100 micrograms. Anecdotal reports in humans suggest that while it produces similar effects to LSD at low to common doses, it displays a notably divergent effects profile as the dose is increased, with it often being noted for producing uniquely immersive "algorithmic" and "warped" visual and auditory distortions, combined with a more "introspective" and "analytical", if not more "neutral" head-space comparable to that of other, typically synthetic psychedelics such as 2C-E.

Relative to LSD, ETH-LAD has also been reported to more readily produce adverse physical effects such as severe and persisting nausea, temperature dysregulation in the form of overheating, and generalized bodily discomfort, particularly at higher doses. This has been speculated to owe itself to an unusually sensitive and unpredictable dose-response curve it seems to possess, as low to common dose experiences are generally described as being very manageable and physically non-threatening.

Very little data exists about the pharmacological properties, metabolism, and toxicity of ETH-LAD, and it has little history of human usage. It has recently become commonly marketed alongside research chemical psychedelic lysergamides like 1P-LSD and AL-LAD as a legal, grey-market alternative to LSD, and commercially distributed through online research chemical vendors. Along with its sensitive dose-response and potentially concerning physical side effects, many reports also suggest that this substance may be overly difficult to use safely for those who are not already very experienced with hallucinogens. Therefore it is highly advised to approach this unusually dose-sensitive, long-lasting, and poorly understood psychedelic substance with the proper amount of precaution and harm reduction practices if choosing to use it.


Substitutive structure of a lysergamide.


ETH-LAD, or 6-ethyl-6-nor-lysergic acid diethylamide, is a synthetic alkaloid of the lysergamide chemical class. ETH-LAD is a structural analog of lysergic acid with an N,N-diethylamide functional group bound to RN of the chemical structure. This core polycyclic structure is an indole derivative and has both overlapping tryptamine and phenethylamine skeletons embedded within its molecular structure (although it is principally classified as a tryptamine). ETH-LAD's structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid).

ETH-LAD does not contain a methyl group substituted at R6 of its nor-lysergic acid skeleton as is the case with LSD; this is represented by the nor- prefix. Instead, ETH-LAD is substituted at R6 with an ethyl group. At carbon 8 of the quinoline, a N,N-diethyl carboxamide is bound in the same configuration of LSD.


ETH-LAD is a chiral compound with two stereocenters at R5 and R8. ETH-LAD, also called (+)-D-ETH-LAD, has an absolute configuration of (5R, 8R).[citation needed]


Further information: Serotonergic psychedelic

As with LSD and other compounds in the lysergamide family, ETH-LAD likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from ETH-LAD's efficacy at the 5-HT2A receptors, although it is likely that like LSD, ETH-LAD also binds to a wide range of different receptors, including multiple different subtypes of serotonin receptors as well as dopamine and adrenoreceptors well.[citation needed]

However, the role of these interactions and how they result in the psychedelic experience continues to remain the subject of on-going scientific investigation.

Pill bottle-o.png

This pharmacology section is incomplete.

You can help by adding to it.

Subjective effects

While the subjective effects of ETH-LAD are reported to largely overlap with those of LSD, it has been noted for the tendency to be more visually and auditorily distortive, introspective, analytical and immersive yet with the capacity to produce pronounced discomforting physical effects like severe and persisting nausea, and temperature dysregulation in the form of overheating past the common dose range in a seemingly unpredictable manner. Due to its high potency and sensitive dose-response, many reports also indicate that the effects of this substance may be overly intense for those who are not already very experienced with psychedelics. Users are advised to approach this substance with caution, use a full array of harm reduction practices, and pay close attention to their physical conditions and environment if choosing to experiment with this substance.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include injury or death.

Physical effects

Visual effects

Cognitive effects

Auditory effects

Multi-sensory effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational ETH-LAD use in humans does not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because ETH-LAD is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried ETH-LAD suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (although nothing can be guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance, especially those that apply to psychedelics and hallucinogens

Tolerance and addiction potential

ETH-LAD is not habit-forming and the desire to use it can actually decrease with use. As with most psychedelics, it is generally considered to have a built-in, self-regulating aspect to it, although cases of its abuse have been reported.[citation needed]

Tolerance to the effects of ETH-LAD build almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to return to baseline (in the absence of further consumption). ETH-LAD presents cross-tolerance with all psychedelics, meaning that after the consumption of ETH-LAD all psychedelics will display a reduced effect.

Dangerous interactions

Although many substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be relatively harmless in low doses of each but can still increase the risk of unpredictable injury or death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. Note that the substances listed below refer to LSD specifically; however, there is no reason to believe they do not apply equally, if not even more so, to relatively unstudied and structurally similar compounds like ETH-LAD as well.

  • Tramadol - Tramadol lowers seizure threshold[4] and psychedelics may cause occasional seizures.[5][6][7]
  • Stimulants - Stimulants may provoke anxiety or thought loops.[8]
  • Lithium - Due to its similiarity to LSD, individuals who take lithium for bipolar disorder or other psychiatric conditions should not take ETH-LAD. There are numerous anecdotal reports of seizures and or psychosis from the LSD-lithium combination.[9][10][11][12]



This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

It is unclear in many countries whether this compound is legal or not and one should take precaution by assuming it is illegal to avoid potential legal issues.

  • United Kingdom: As of January 7th, 2015, ETH-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A drug.[13]
  • United States - ETH-LAD is unscheduled in the United States. It may be considered an analogue of LSD (which is a Schedule I drug under the Controlled Substances Act). As such, the sale for human consumption or the use for illicit non-medical or scientific research could be prosecuted as crimes under the Federal Analogue Act.[citation needed]
  • Switzerland - ETH-LAD is scheduled as of the 1st of December 2015.[14]
  • Latvia - ETH-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1st, 2015.[15]

See also

External links


  • Hoffman, A. J., & Nichols, D. E. (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N (6)-alkyl norlysergic acid N, N-diethylamide derivatives. Journal of Medicinal Chemistry, 28(9), 1252-1255.
  • Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995). LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 118(4), 401-409.
  • Niwaguchi, T., Nakahara, Y., & Ishii, H. (1976). Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 96(5), 673-678. PMID 987200.
  • Pfaff, R. C., Huang, X., Marona-Lewicka, D., Oberlender, R., & Nichols, D. E. (1994). Lysergamides Revisited. NIDA Research Monograph, 146, 52-73. PMID: 8742794.


  1. 1.0 1.1 1.2 National Center for Biotechnology Information. PubChem Compound Database; CID=44457783, (accessed May 5, 2017).
  2. Shulgin, A., & Shulgin, A. (1991). Erowid Online Books: "TIHKAL" - #12. ETH-LAD. Retrieved April 14, 2017.
  3. Hoffman, A. J., & Nichols, D. E. (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N (6)-alkyl norlysergic acid N, N-diethylamide derivatives. Journal of Medicinal Chemistry, 28(9), 1252-1255.
  4. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
  5. Tripsit Factsheets - LSD |
  6. Fisher, D. D., & Ungerleider, J. T. (1967). Grand mal seizures following ingestion of LSD. California Medicine, 106(3), 210. PMCID: PMC1502729
  7. Question ID: 2837 (Ask Erowid) |
  8. Tripsit Factsheets - LSD |
  9. | LSD Interactions by Erowid
  10. Wanderli. "A Nice Little Trip to the Hospital: An Experience with Lithium & LSD (ID 83935)". Oct 3, 2010.
  11. MissDja1a. "Having a Seizure and Passing Out: An Experience with Lithium & LSD (ID 75153)". Dec 16, 2008.
  12. Reddit account of seizure on LSD + Lithium |
  13. ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Retrieved 10 June 2014. 
  14. Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (Betäubungsmittelverzeich nisverordnung, BetmVV - EDI) |
  15. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2.4.punkts) |